stockrow
Friday 6 November 2026
Export RGC’s income statement to Excel — free account
Regencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
5.17
0.10
−1.90%
Follow RGC
Alert me
Regencell Bioscience Holdings Limited (RGC) Operating cash flow
Regencell Bioscience Holdings Limited's operating cash flow for fiscal 2026 was −$7.7M, compared with −$3.1M in fiscal 2025. Over the past ten years it has ranged from −$7.7M (fiscal 2026) to −$391.0K (fiscal 2019) — the current reading is the lowest in ten years. Regencell Bioscience Holdings Limited ranks 67th of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2026 | −$7.7M | — |
| FY2025 | −$3.1M | — |
| FY2024 | −$4.0M | — |
| FY2023 | −$5.0M | — |
| FY2022 | −$5.3M | — |
| FY2021 | −$767.3K | — |
| FY2020 | −$726.6K | — |
| FY2019 | −$391.0K | — |
Against its own ten years
Low −$7.7M
High −$391.0K
Ten-year median
−$3.6M
Current reading's percentile
13
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | $367.5M |
| TRLV Trulieve Cannabis Corp. compare | $242.5M |
| PRGO Perrigo Company plc compare | $240.6M |
| PBH Prestige Consumer Healthcare Inc. compare | $229.8M |
| XERS Xeris Biopharma Holdings, Inc. compare | $73.6M |
| ALVO Alvotech compare | −$11.8M |
| RGC Regencell Bioscience Holdings Limited | −$14.7M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −$124.8M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$126.6M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item